LONDON: IQ-AI Limited announced that the US Food and Drug Administration (FDA) has granted 510(k) market clearance for the Liver Surface Nodularity (LSN) software application. Earlier this year, IQ-AI’s subsidiary, Imaging Biometrics, LLC (“IB”), entered into a business agreement with the owners of LSN, AI Metrics, LLC, which granted IB global rights to manufacture, market,…